Scholar Rock (SRRK) reported a Q1 loss Thursday of $0.83 per diluted share, widening from a loss of $0.67 a year earlier.

Analysts polled by FactSet expected a loss of $0.80.

The biotech startup reported no revenue for the quarter ended March 31, as expected by analysts.

Cash, cash equivalents, and marketable securities as of March 31 totalled $479.9 million.